comparemela.com

Page 4 - Simmunome News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Immunome Licenses ZPC-21, And ADC Platform Technology From Zentalis

Immunome, Inc. (IMNM) and Zentalis Pharmaceuticals, Inc. (ZNTL) have entered into an exclusive, worldwide license agreement under which Immunome has licensed from Zentalis ZPC-21, a preclinical ROR1 antibody-drug conjugate which is on track for IND submission in first quarter 2025, and Zentalis' ADC platform technology.

Clay siegallImmunome incMore such health newsZentalis pharmaceuticals incZentalis pharmaceuticals

Individual investors who hold 51% of Immunome, Inc (NASDAQ:IMNM) gained 15%, institutions profited as well

Key Insights Immunome's significant individual investors ownership suggests that the key decisions are influenced by.

Michael rapoportMorphimmune incLongboat family officeCompany ownershipImmunome incPrivate companiesNstitutional ownershipNdividual investorsNsider ownershipHare registry

A|I: The AI Times – John Grisham, George R R Martin headline OpenAI s latest copyright fight

The AI Times is a weekly newsletter covering the biggest AI, machine learning, big data, and automation news from around the globe.

United statesPablo listingartJohn grishamSandi campbellGeorgerr martinCisco systemsThe globe and mailWorkforce development teamInnovation clusterCraft venturesZoho inventoryPackage geometryUber freightWaabi driverNorth americanFuture workforce development team

Raquel Urtasun reunites with Uber in autonomous trucking partnership

Welcome to BetaKit's startup stories of the week! Here, you will find the week's most important news, features, and editorials published on BetaKit.

United statesSean oconnorSandi campbellMichael kwokPablo listingartAlex riehlCarleton universityWorkforce development teamDigital ventures fundWaabi driverUber freightConexus venture capitalSeano connorVentures fundInnovation clusterExecutive director

Simmunome secures $2 million to make clinical trials more efficient with AI

Using artificial intelligence, Montréal-based Simmunome aims to help predict whether drug candidates will succeed or fail in clinical trials.

United statesArmstrong muriraNardin nakhlaTheodorus investmentSandpiper venturesFront row venturesAltis labsDeep genomicsValence discoveryFondsd investissement eurêkaBkr capitalAcet capitalClinical trials

vimarsana © 2020. All Rights Reserved.